



JENNIFER KENT
DIRECTOR

State of California—Health and Human Services Agency
Department of Health Care Services



EDMUND G. BROWN JR.
GOVERNOR

September 30, 2016

CHDP Provider Information Notice No.: 16-07

TO: ALL CHILD HEALTH DISABILITY AND PREVENTION (CHDP)
PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE
PLANS

SUBJECT: CHDP PROGRAM ADD NEW VACCINE PROCEDURE CODES 93, 94,
AND 95 FOR 9 VALENT HUMAN PAPILLOMA VIRUSES (Gardasil9®)

The purpose of this Provider Information Notice (PIN) is to inform you of the addition of two (2) new CHDP Program Procedure Codes. Effective October 1, 2015: For recipients' ages nine (9) through 18 years and 11 months, CHDP Program code 93 can be used to administer CHDP Program Vaccine for Children (VFC) fees. For recipients who are 19 through 20 years and 11 months of age, use code 94 and 95 for payments related to human papilloma viruses (HPV 9) Vaccine for non-VFC beneficiaries.

Medi-Cal Code	Medi-Cal Description	Age Group	CHDP Code	CHDP Description	Reimbursement
90651	HPV9	9 years through 18 years 11 months	93	Administration Fee	\$9
90651	HPV9	19 years through 20 years 11 months	94 95	Non-VFC 3 dose schedule	\$162.45

Background

The Advisory Committee on Immunization Practices (ACIP) recommends human papilloma virus (HPV) vaccine for routine vaccination at age 11 or 12 years. The vaccination series can be started beginning at age nine (9) years. Vaccination beginning at age nine (9) years is recommended for children and youth with any history of sexual abuse or assault. The ACIP also recommends vaccination for females aged 13 through 26 years and males aged 13 through 21 years not vaccinated previously. Vaccination is also recommended through age 26 years for males who have sexual contact with other males and for immunocompromised persons (including those with

September 30, 2016

human immunodeficiency virus [HIV] infection, if not vaccinated previously). HPV 9 is administered in a three (3) dose schedule. The second dose is administered at least one (1) to two (2) months after the first dose and the third dose at least six (6) months after the first dose. If the vaccine schedule is interrupted, the vaccination series does not need to be restarted. If a patient started the HPV vaccination series with HPV 2 (Cervarix®) or HPV 4 (Gardasil®), HPV 9 may be used to continue or complete the HPV vaccination series.

Information from the California Department of Public Health Immunization Branch about HPV 9/Gardasil9® is available at:

http://eziz.org/assets/docs/VFC_Letters/vfcletter_2015_6_Gardasil.pdf.

The Morbidity and Mortality Weekly Report (MMWR) on the Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices.

The full MMWR is available on Centers for Disease Control and Prevention:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm>.

Important Note: The above comprehensive HPV vaccine recommendations are provided for your information; VFC HPV vaccines are only available for eligible patients, ages nine (9) through 18 years. Thus the CHDP Program pays for HPV 9 vaccine administration for VFC clients, nine (9) years through 18 years 11 months, and for non-VFC vaccine administration plus HPV 9 vaccine 19 years through 20 years 11 months.

Effective October 1, 2015. CHDP Program Providers can submit claims for HPV 9 retroactively to October 1, 2015. Previously denied claims will have to be resubmitted.

Please refer to CHDP Program Provider Manual rates max section (Enclosure).

Conflict edits are with codes 76, 77+78 and 85, 86+87.

Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions, please contact your local CHDP program.

Sincerely,

ORIGINAL SIGNED BY PATRICIA MCCLELLAND

Patricia McClelland, Chief
Systems of Care Division